Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Serina TherapeuticsSER +1.49%12 Cash-to-Debt is 7.18 as of Jun. 2026, which is 161% above its 10-year median of 2.75. GuruFocus rates SER with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,398 Biotechnology companies, Serina Therapeutics ranks better than 50.57% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Serina Therapeutics's cash to debt ratio for the quarter that ended in Jun. 2026 was 7.18.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Serina Therapeuticscould pay off its debt using the cash in hand for the quarter that ended in Jun. 2026.
The historical rank and industry rank for Serina Therapeutics's Cash-to-Debt or its related term are showing as below:
SER'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.28 Med: 2.75 Max: 32.65
Current: 7.18
During the past 5 years, Serina Therapeutics's highest Cash to Debt Ratio was 32.65. The lowest was 0.28. And the median was 2.75.
SER's Cash-to-Debt is ranked better than 50.57% of 1398
companies
in the Biotechnology industry
Industry Median: 6.68
vs SER: 7.18
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Serina Therapeutics Cash-to-Debt Related Terms
Serina Therapeutics Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Serina Therapeutics's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
For the Biotechnology subindustry, Serina Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Serina Therapeutics Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Serina Therapeutics's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Serina Therapeutics's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Serina Therapeutics (SER) has a Cash-to-Debt of 7.18 as of Jun. 2026. This is 161% above median its historical median of 2.75. Over the past decade, Serina Therapeutics' Cash-to-Debt has ranged from 0.28 to 32.65. According to the industry distribution chart, Serina Therapeutics ranks #691 out of 1398 companies in the Biotechnology industry, placing it in the top 49.4%.
Is Serina Therapeutics' Cash-to-Debt too high?
Serina Therapeutics' current Cash-to-Debt of 7.18 is 161% above median its 10-year median of 2.75. Over the past 10 years, this metric has ranged from a low of 0.28 to a high of 32.65. The Biotechnology industry median Cash-to-Debt is 6.68. Serina Therapeutics' value of 7.18 is 7.5% above this industry median. Based on the distribution chart, Serina Therapeutics ranks #691 out of 1398 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Serina Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Serina Therapeutics' Cash-to-Debt compare to HRTX and IMA?
According to the Biotechnology industry distribution chart, Serina Therapeutics ranks #691 out of 1398 companies for Cash-to-Debt. This puts Serina Therapeutics in the upper half of its industry. The industry median Cash-to-Debt is 6.68. Serina Therapeutics' value of 7.18 is 7.5% above this benchmark. Historically, Serina Therapeutics' own Cash-to-Debt has ranged from 0.28 to 32.65 over the past decade. While the company's 10-year median is 2.75 vs. the industry median of 6.68, Serina Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.68, based on 1,398 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Serina Therapeutics's current Cash-to-Debt of 7.18 is 7.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Serina Therapeutics's current Cash-to-Debt is 7.18, which is 161% above median its own 10-year median of 2.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Serina Therapeutics stock overvalued right now?
Serina Therapeutics (SER) has a current Cash-to-Debt of 7.18. The current Cash-to-Debt is 7.18, which is 161% above median its 10-year median of 2.75 and 7.5% above the Biotechnology industry median of 6.68. Serina Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Serina Therapeutics (SER), the current Cash-to-Debt is 7.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The company has one reportable segment relating to the research and development of its POZ platform. The segment derives its revenues from Grant revenue. Its main product candidate, SER-252 for advanced Parkinson's disease, is anticipated to enter clinical trials.
12GF Score
Get the complete analysis for SER
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SER has been successfully added to your 
